Goldman Sachs’s Moderna MRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $8.75M | Buy |
+125,000
| New | +$6.47M | ﹤0.01% | 3364 |
|
|
2026
Q1 | – | Sell |
-14,600
| Closed | -$431K | – | 6809 |
|
|
2025
Q4 | $431K | Hold |
14,600
| – | – | ﹤0.01% | 5687 |
|
|
2025
Q3 | $377K | Hold |
14,600
| – | – | ﹤0.01% | 5657 |
|
|
2025
Q2 | $403K | Sell |
14,600
-109,900
| -88% | -$2.89M | ﹤0.01% | 5285 |
|
|
2025
Q1 | $3.53M | Buy |
124,500
+74,900
| +151% | +$2.66M | ﹤0.01% | 3685 |
|
|
2024
Q4 | $2.06M | Sell |
49,600
-174,700
| -78% | -$8.35M | ﹤0.01% | 4255 |
|
|
2024
Q3 | $15M | Buy |
224,300
+97,800
| +77% | +$8.98M | ﹤0.01% | 2319 |
|
|
2024
Q2 | $15M | Buy |
126,500
+19,000
| +18% | +$2.4M | ﹤0.01% | 2120 |
|
|
2024
Q1 | $11.5M | Sell |
107,500
-66,200
| -38% | -$6.67M | ﹤0.01% | 2354 |
|
|
2023
Q4 | $17.3M | Buy |
173,700
+104,300
| +150% | +$8.77M | ﹤0.01% | 2037 |
|
|
2023
Q3 | $7.17M | Sell |
69,400
-20,600
| -23% | -$2.3M | ﹤0.01% | 2670 |
|
|
2023
Q2 | $10.9M | Buy |
90,000
+3,600
| +4% | +$480K | ﹤0.01% | 2362 |
|
|
2023
Q1 | $13.3M | Sell |
86,400
-181,600
| -68% | -$30M | ﹤0.01% | 2167 |
|
|
2022
Q4 | $48.1M | Buy |
268,000
+146,700
| +121% | +$24M | 0.01% | 1203 |
|
|
2022
Q3 | $14.3M | Buy |
121,300
+81,500
| +205% | +$12.4M | ﹤0.01% | 2161 |
|
|
2022
Q2 | $5.68M | Sell |
39,800
-107,000
| -73% | -$15.3M | ﹤0.01% | 3016 |
|
|
2022
Q1 | $25.3M | Sell |
146,800
-6,400
| -4% | -$1.08M | 0.01% | 1858 |
|
|
2021
Q4 | $38.9M | Buy |
153,200
+17,000
| +12% | +$4.97M | 0.01% | 1548 |
|
|
2021
Q3 | $52.4M | Buy |
136,200
+53,800
| +65% | +$19.8M | 0.01% | 1254 |
|
|
2021
Q2 | $19.4M | Hold |
82,400
| – | – | ﹤0.01% | 2071 |
|
|
2021
Q1 | $10.8M | Buy |
82,400
+45,600
| +124% | +$6.61M | ﹤0.01% | 2497 |
|
|
2020
Q4 | $3.84M | Buy |
36,800
+6,100
| +20% | +$617K | ﹤0.01% | 3208 |
|
|
2020
Q3 | $2.17M | Buy |
+30,700
| New | +$2.14M | ﹤0.01% | 3506 |
|
|
2020
Q2 | – | Sell |
-8,700
| Closed | -$261K | – | 5379 |
|
|
2020
Q1 | $261K | Buy |
+8,700
| New | +$200K | ﹤0.01% | 4583 |
|
|
2019
Q4 | – | Sell |
-19,300
| Closed | -$307K | – | 5341 |
|
|
2019
Q3 | $307K | Sell |
19,300
-67,800
| -78% | -$1M | ﹤0.01% | 4676 |
|
|
2019
Q2 | $1.27M | Buy |
87,100
+17,100
| +24% | +$367K | ﹤0.01% | 3821 |
|
|
2019
Q1 | $1.42M | Buy |
+70,000
| New | +$1.3M | ﹤0.01% | 3853 |
|
Other funds holding MRNA
TP
Goldman Sachs's MRNA Position: Q2 2026 in Review
Goldman Sachs reduced its Moderna (MRNA) stake by 29% in Q2 2026, selling an estimated $99.9M and leaving 4,671,950 shares worth $327M. The position accounts for 0.03% of the portfolio, ranked #558.
Goldman Sachs first reported a position in MRNA in Q4 2018 and has held it in 31 quarters since. The position peaked at $610M in Q3 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.
- Goldman Sachs held 4,671,950 shares of Moderna worth $327M as of Q2 2026.
- Goldman Sachs sold 1,931,747 Moderna shares in Q2 2026, an estimated $99.9M.
- Moderna made up 0.03% of Goldman Sachs's portfolio in Q2 2026, its #558 holding.
- Goldman Sachs first reported a position in Moderna in Q4 2018 and has held it in 31 quarters since.
- Goldman Sachs's Moderna position peaked at $610M in Q3 2021.
- 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.
Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.